% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • justarook04 justarook04 Mar 8, 2014 1:39 PM Flag

    About 10 months ago (May) Part 2

    continued from Biomedreports (May 2013):

    "Amikacin, Ingredient in Arikace is FDA approved antibiotic for CF. But it wasn't delivered well in lung.Insmed's Liposome technology solves this delivery problem by placing amikacin into a liposome, which allows an extention duration of drug efficacy. Amikacin efficacy suggests that the drug is potentially better than TOBI which brings in annual revenues around $400m.With a market cap near $295M, Insmed appears to be undervalued by at least $100M, if not more.

    As of this morning, Lazard Capital has started its coverage of Insmed with a "buy" rating and a 1 year target of $21 a share." As of late 2013,

    Scott Matusow indicated he was long INSM at that time.

    Lazard has increased their PT to $24 and then to $28.

    Canaccord has increased their PT from $18 to $30 in this time frame.

    Leerink Swann went from $12 to $22 in this time frame.

    Sentiment: Buy

14.07+0.03(+0.21%)Oct 24 4:00 PMEDT